Cyclopharm Ltd

Cyclopharm's capital structure shows a current ratio of 2.53, indicating moderate liquidity, but the company has negative net cash after subtracting total debt, signaling potential liquidity constraints. The debt-to-equity ratio of 0.29 suggests a relatively conservative leverage position, with long-term debt amounting to 7.74 million AUD against total equity of 27.11 million AUD. However, the company's operating cash flow is negative at -17.33 million AUD, and free cash flow is also negative at -17.56 million AUD, indicating ongoing cash burn. Profitability metrics are weak, with a return on equity of -63.52% and a return on assets of -37.35%, both significantly below industry norms for medical equipment firms. The company reported a net loss of 17.22 million AUD and an operating loss of 17.53 million AUD, reflecting poor operational performance. Gross profit of 17.85 million AUD is insufficient to cover operating expenses, highlighting inefficiencies in cost management. The company's revenue is concentrated in a single product line, Technegas, which is a diagnostic lung imaging technology used in approximately 65 countries. Cyclopharm's business is heavily dependent on the continued demand for Technegas and its associated equipment and consumables, with no significant diversification into other product lines or geographic regions. Growth trajectory is negative, with the company reporting a net loss in the latest period and no clear path to profitability. Analysts have assigned a mean price target of 1.00 AUD, with a "hold" recommendation, indicating limited upside potential. Cyclopharm's revenue of 32.33 million AUD is not growing, and the company is burning cash, which could limit its ability to invest in R&D or expand its market share. Risk factors include liquidity constraints, as the company has negative net cash after subtracting total debt, and a high probability of continued operating losses. The risk assessment indicates a medium liquidity risk and low dilution risk, but the company's negative operating cash flow and free cash flow suggest ongoing financial stress. Cyclopharm has not issued new shares recently, and there is no indication of near-term dilution pressure. Recent events include the continued distribution of Technegas in 65 countries, but there are no recent filings or transcripts indicating new product launches, partnerships, or strategic shifts. The company's focus remains on its core diagnostic imaging technology, with no significant changes in its business model or market strategy.